Clinical trials: Psoriasis Patients
Psoriasis
Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab
The objective of this non-interventional, observational study is to assess the effect of adalimumab on health-related quality of life in participants with Psoriasis in Korea.
- Trial name
- RAPSODI (NCT03099083)
- Where
- 12 sites in South Korea
- Volunteers
- 97 people
- Sponsor
- AbbVie
Psoriasis
Evaluation of IL 12B Genetic Polymorphism (rs3213094)
Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales.
- Trial name
- NCT07128472
- Testing
- Humira
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- South Valley University
Psoriasis Vulgaris, Diabetes Type 2
Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
The use of semaglutide in patients with DMT2 and psoriasis contributes to improving the clinical picture of psoriasis and reducing the inflammatory response
- Trial name
- NCT06475586
- Testing
- Semaglutide
- Where
- Bosnia and Herzegovina
- Volunteers
- 30 people
- Sponsor
- University of Banja Luka
SARS-CoV-2, Systemic Lupus Erythematosus
Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients…
- Conditions
- SARS-CoV-2, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's Syndrome
- Trial name
- COVCALL (NCT04345159)
- Testing
- Questionnaire by phone call
- Where
- France
- Volunteers
- 572 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Moderate to Severe Psoriasis
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
This is a single-center, open-label, pilot study. A total of 18 subjects will be enrolled in this 6 month study to evaluate whether the response to intralesional alefacept injections prior to the standard course of…
- Trial name
- NCT00678470
- Testing
- Intralesional Alefacept
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Psoriasis
Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)
This is an open-label, multicenter, parallel-group comparison study of the efficacy, safety, and tolerability of infliximab therapy in adult patients suffering from chronic plaque psoriasis (psoriasis vulgaris).
- Trial name
- NCT00254982
- Testing
- Infliximab
- Volunteers
- 593 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis Vulgaris
Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris
To gather insight on how product attributes affect usability by investigating the factors that are thought to influence patient preference to topical anti-psoriatic treatments.
- Trial name
- NCT02310646
- Testing
- LEO 90100 Aerosol Foam, Daivobet® gel
- Where
- Canada
- Volunteers
- 219 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)
Biologics such as risankizumab are currently the most effective treatment option for patients with moderate to severe psoriasis.
- Trial name
- BIOLOPTIM-RIS (NCT05685940)
- Testing
- Venapuncture, Patient questionnaires
- Where
- 7 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Psoriasis
Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
In this study, participants will have 3 or 4 total study visits over approximately 10 total weeks. There is a two week medication washout period in between the 1st and 2nd visits.
- Trial name
- NCT06399432
- Testing
- Mediterranean Diet
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University Hospitals Cleveland Medical Center
Psoriasis
Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients
The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.
- Trial name
- ESSENCE (NCT00408187)
- Testing
- voclosporin, Ciclosporin
- Where
- 49 sites in Canada, Germany and 1 more
- Volunteers
- 642 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Plaque Psoriasis Patients
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
- Trial name
- NCT06842199
- Testing
- ICP-488 Tablets
- Where
- 46 sites in China
- Volunteers
- 383 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Psoriasis
An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00454584
- Testing
- CNTO 1275 45 mg, CNTO 1275 90 mg, Etanercept 50 mg
- Volunteers
- 903 people
- Sponsor
- Centocor, Inc.
Psoriasis, Plaque
A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis
The purpose of this study is to assess the severity of plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches.
- Trial name
- NCT02274363
- Testing
- No Intervention
- Where
- 16 sites in Brazil
- Volunteers
- 1,131 people
- Sponsor
- Janssen Pharmaceutica
Mesenchymal Stromal Cells, Psoriasis
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis
The purpose of this study is to evaluate the efficacy and safety of Adipose derived Mesenchymal Stem Cells (AD-MSCs) plus Calpocitriol Ointment with moderate to severe psoriasis.
- Conditions
- Mesenchymal Stromal Cells, Psoriasis, Drug Effect, Drug Toxicity
- Trial name
- NCT03392311
- Testing
- Calcipotriol ointment, adipose-derived multipotent mesenchymal stem cells
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Psoriasis
A Randomized Control Trial of Patient-initiated Hospital Follow-up for Patients With Psoriasis
The primary objective of this research protocol is to evaluate the health related quality of life and efficacy of patient-initiated hospital follow-up for patients with moderate to severe psoriasis.
- Trial name
- NCT02382081
- Testing
- Patient-initiated shared care
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Psoriasis, Neuroinflammation
Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis
Objectives: To identify peripheral neuroinflammatory markers in patients suffering from major depression or psoriasis in relation to affective symptoms (anxiety, depression, irritability), fatigue and cognitive symptoms; and…
- Conditions
- Psoriasis, Neuroinflammation, Major Depressive Disorder, Cognitive Symptom
- Trial name
- INPSYDER (NCT04423471)
- Testing
- Sociodemographic variables
- Where
- Spain
- Sponsor
- Germans Trias i Pujol Hospital
Psoriasis
A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects…
- Trial name
- NCT05451199
- Testing
- ICP-488
- Where
- 7 sites in China
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Psoriatic Arthritis
Initial Treatment With Golimumab in Early PsA
The investigators will perform a 22-week randomized, double-blind, placebo-controlled trial of golimumab + methotrexate (MTX) versus methotrexate alone in methotrexate-naïve patients with Psoriatic Arthritis (PsA).
- Trial name
- NCT01871649
- Testing
- golimumab, methotrexate
- Where
- 2 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Plaque Psoriasis, Non-alcoholic Fatty Liver Disease
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study was to assess the therapeutic efficacy of secukinumab on the psoriatic skin and to explore the anti-inflammatory (reduction of hepatic inflammation and cell damage), anti-steatotic (reduction of hepatic…
- Trial name
- pINPOINt (NCT04237116)
- Testing
- Investigational Arm - secukinumab
- Where
- 8 sites in Germany, Spain
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA)
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis…
- Trial name
- NCT07166315
- Testing
- observational study
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- Adelphi Real World
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.